Other alternative activations in resistant gastric cancer include another downstream effector of HER2, FGF3, and RAS/PI3K, and MAPK/ERK signaling pathways, mainly through the activation of other members of the ERBB family, such as EGFR or HER3. The gene discussed is ERBB2; the disease is gastric cancer.